Adverse events2,008

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 2,008

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anaemia	Blood and lymphatic system disorders	Vilaprisan 2 mg A1 (3/1 Regimen) - Treatment Emergent AEs	4	349	4
other	Anaemia	Blood and lymphatic system disorders	Vilaprisan 2 mg A2 (6/2 Regimen) - Treatment Emergent AEs	8	347	8
other	Anaemia	Blood and lymphatic system disorders	Vilaprisan 2 mg A3 (3/2 Regimen) - Treatment Emergent AEs	3	177	3
other	Anaemia	Blood and lymphatic system disorders	Standard of Care B - Treatment Emergent AEs	29	365	30
other	Anaemia	Blood and lymphatic system disorders	Vilaprisan 2 mg A1 (3/1 Regimen) - Post Treatment AEs	10	349	10
other	Anaemia	Blood and lymphatic system disorders	Vilaprisan 2 mg A2 (6/2 Regimen) - Post Treatment AEs	12	347	12
other	Anaemia	Blood and lymphatic system disorders	Vilaprisan 2 mg A3 (3/2 Regimen) - Post Treatment AEs	8	177	8
other	Anaemia	Blood and lymphatic system disorders	Standard of Care B - Post Treatment AEs	1	365	1
other	Fatigue	General disorders	Vilaprisan 2 mg A1 (3/1 Regimen) - Treatment Emergent AEs	13	349	13
other	Fatigue	General disorders	Vilaprisan 2 mg A2 (6/2 Regimen) - Treatment Emergent AEs	20	347	20
other	Fatigue	General disorders	Vilaprisan 2 mg A3 (3/2 Regimen) - Treatment Emergent AEs	6	177	6
other	Fatigue	General disorders	Standard of Care B - Treatment Emergent AEs	18	365	20
other	Fatigue	General disorders	Vilaprisan 2 mg A1 (3/1 Regimen) - Post Treatment AEs	2	349	2
other	Fatigue	General disorders	Vilaprisan 2 mg A2 (6/2 Regimen) - Post Treatment AEs	3	347	3
other	Fatigue	General disorders	Vilaprisan 2 mg A3 (3/2 Regimen) - Post Treatment AEs	3	177	3
other	Fatigue	General disorders	Standard of Care B - Post Treatment AEs	2	365	2
other	Nasopharyngitis	Infections and infestations	Vilaprisan 2 mg A1 (3/1 Regimen) - Treatment Emergent AEs	37	349	51
other	Nasopharyngitis	Infections and infestations	Vilaprisan 2 mg A2 (6/2 Regimen) - Treatment Emergent AEs	42	347	55
other	Nasopharyngitis	Infections and infestations	Vilaprisan 2 mg A3 (3/2 Regimen) - Treatment Emergent AEs	14	177	15
other	Nasopharyngitis	Infections and infestations	Standard of Care B - Treatment Emergent AEs	12	365	16

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03194646/events

API reference For AI assistants

Adverse events2,008

Sources 3

Read this list from software.